- Belizatinib
-
- $36.00 / 1mg
-
2026-03-13
- CAS:1357920-84-3
- Min. Order:
- Purity: 99.48%
- Supply Ability: 10g
|
| | Belizatinib Basic information |
| Product Name: | Belizatinib | | Synonyms: | Belizatinib;Belizatinib (TSR011);TSR-011;CS-2493;TSR011; TSR011; TSR 011; BELIZATINIB;Benzamide, 4-fluoro-N-[6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-1-[cis-4-[[(1-methylethyl)amino]carbonyl]cyclohexyl]-1H-benzimidazol-2-yl]-;TSR011,Trk Receptor,CD246,ALK tyrosine kinase receptor,Tropomyosin related kinase receptor,TSR 011,inhibit,Cluster of differentiation 246,Belizatinib,Inhibitor,Anaplastic lymphoma kinase,Anaplastic lymphoma kinase (ALK);4-Fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-(cis-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2-yl)benzamide | | CAS: | 1357920-84-3 | | MF: | C33H44FN5O3 | | MW: | 577.73 | | EINECS: | | | Product Categories: | | | Mol File: | 1357920-84-3.mol |  |
| | Belizatinib Chemical Properties |
| density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:30.0(Max Conc. mg/mL);51.93(Max Conc. mM)
DMSO:143.33(Max Conc. mg/mL);248.08(Max Conc. mM)
Ethanol:65.0(Max Conc. mg/mL);112.5(Max Conc. mM) | | form | A crystalline solid | | pka | 12.55±0.43(Predicted) | | color | White to off-white |
| | Belizatinib Usage And Synthesis |
| Description | Belizatinib, also known as TSR-011, is an oral inhibitor of ALK and TRK. | | Description | Belizatinib is an inhibitor of anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively). | | Uses | Belizatinib is used in treating diseases via targeted modulation of gene signaling networks. | | in vivo | Belizatinib (TSR-011) exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1]. | | IC 50 | TrkA; TrkB; TrkC | | References | [1] H. ARKENAU. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.[J]. Journal of Clinical Oncology, 2015, 33 1: 8063-8063. DOI: 10.1200/jco.2015.33.15_suppl.8063 |
| | Belizatinib Preparation Products And Raw materials |
|